Restoration of vision with new generation Artficial Theranostic Cornea

使用新一代人工角膜治疗恢复视力

• 批准号: MR/T030968/1
• 负责人: Hirak Patra
• 金额: $ 174.96万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FT030968%2F1
• 关键词: Restoration; vision; new; generation; Artficial

The cornea is the outermost transparent part of the eye, which acts as the main refractive element to transmit light to the retina, giving us sight. Any damage or disease to the cornea that causes permanent loss of its transparency results in corneal blindness. The World Health Organization in their 2017 report estimated that 253 million people live with visual impairment, with 23 million suffering with one eye condition. It is clear that increasing donations alone will no way be sufficient to make up for the donor cornea shortage. More importantly, even if donor corneas were available, patients with severe pathologies would not benefit from donor as they are at high risk of rejecting the donor cornea, thereby necessitating an alternative approach. I shall develop nanotechnology assisted pro-regenerative artificial cornea (ARCs) that can combat the clinical challenges associated with corneal blindness to promote functional regeneration and restore vision. ARCs will be developed together with an in-built theranostic (diagnostic cum therapeutic) monitoring system to identify and treat factors leading to rejection and failure of the transplant. The new artificial cornea will be anti-infective, anti-inflammatory and will have cell-proliferative activity. Information will be gathered in this pre-clinical project would guide towards future clinical trials and in translation of research to patients with corneal blindness. My proposed approach is never been addressed and is completely new to the field to restore vision might revolutionise the present cornea transplantation regime could have significant impact and quality of life in UK and beyond.

角膜是眼睛的最外部透明部分，它是将光传递到视网膜的主要折射元素，从而使我们看到了。对角膜的任何损害或疾病导致其透明度永久损失导致角膜失明。世界卫生组织在2017年的报告中估计，有2.53亿人患有视觉障碍，有2300万人患有一种眼睛状况。显然，仅增加捐款就不足以弥补捐赠者角膜短缺。更重要的是，即使有供体角膜可用，患有严重病理的患者也不会受益于捐助者，因为他们有拒绝捐赠者角膜的高风险，因此需要采取另一种方法。我将开发纳米技术的辅助促进性人造角膜（ARC），以应对与角膜失明相关的临床挑战，以促进功能性再生并恢复视力。 ARC将与内部静脉结构的（诊断和治疗性）监测系统一起开发，以识别和治疗导致移植拒绝和失败的因素。新的人造角膜将具有抗感染，抗炎作用，并具有细胞增殖活性。该信息将在此临床前项目中收集，将指导将来的临床试验以及将研究转化为角膜失明的患者。我提出的方法从未得到解决，并且对恢复视力的领域是全新的，可能会彻底改变目前的角膜移植制度，在英国及其他地区可能会产生重大影响和生活质量。

项目成果

Rational design of peptide-based implants for corneal bioengineering.

• DOI: 10.1016/j.copbio.2023.102947
• 发表时间: 2023-05
• 期刊: Current opinion in biotechnology
• 影响因子: 7.7
• 作者: Bapan Pramanik;M. M. Islam-M.;H. Patra

Nanomedicine: controlling nanoparticle clearance for translational success.

• DOI: 10.1016/j.tips.2022.05.001
• 发表时间: 2022-05
• 期刊: Trends in pharmacological sciences
• 影响因子: 13.8
• 作者: Geyunjian H Zhu;Alex B.C. Gray;H. Patra

Chemical Crosslinker-free Pro-regenerative Corneal Implants

不含化学交联剂的促再生角膜植入物

• 发表时间: 2022
• 作者: Islam M

Innate Immune Invisible Ultrasmall Gold Nanoparticles-Framework for Synthesis and Evaluation.

• DOI: 10.1021/acsami.1c02834
• 发表时间: 2021-05-26
• 期刊: ACS applied materials & interfaces
• 影响因子: 9.5
• 作者: Zhu GH;Azharuddin M;Islam R;Rahmoune H;Deb S;Kanji U;Das J;Osterrieth J;Aulakh P;Ibrahim-Hashi H;Manchanda R;Nilsson PH;Mollnes TE;Bhattacharyya M;Islam MM;Hinkula J;Slater NKH;Patra HK
• 通讯作者: Patra HK

Crosslinker-free collagen gelation for corneal regeneration.

用于角膜再生的无交联剂胶原凝胶。

• DOI: 10.1038/s41598-022-13146-9
• 发表时间: 2022-06-01
• 期刊: SCIENTIFIC REPORTS
• 影响因子: 4.6
• 作者: Islam, Mohammad Mirazul;Chivu, Alexandru;AbuSamra, Dina B.;Saha, Amrita;Chowdhuri, Sumit;Pramanik, Bapan;Dohlman, Claes H.;Das, Debapratim;Argueso, Pablo;Rajaiya, Jaya;Patra, Hirak K.;Chodosh, James
• 通讯作者: Chodosh, James